Saved in:
| Main Authors: | Tibor Szarvas, Henning Reis |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2024
|
| Subjects: | |
| Online Access: | https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.6300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Molecular subtype concordance and metastatic patterns in muscle‐invasive bladder cancer
by: Csilla Olah, et al.
Published: (2026)
by: Csilla Olah, et al.
Published: (2026)
Use of UV mutational signatures to distinguish between cutaneous and pulmonary primary squamous cell carcinoma
by: Jeffrey S. Ross, et al.
Published: (2024)
by: Jeffrey S. Ross, et al.
Published: (2024)
Deep learning‐based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images
by: Jun Hyeong Park, et al.
Published: (2024)
by: Jun Hyeong Park, et al.
Published: (2024)
The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma
by: Ziqing Zeng, et al.
Published: (2024)
by: Ziqing Zeng, et al.
Published: (2024)
TP53 mutations in urothelial carcinoma: not all one and the same†
by: Alexis R Barr, et al.
Published: (2024)
by: Alexis R Barr, et al.
Published: (2024)
Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
by: Csilla Olah, et al.
Published: (2025)
by: Csilla Olah, et al.
Published: (2025)
DNA ‐hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation
by: Yasunobu Mano, et al.
Published: (2025)
by: Yasunobu Mano, et al.
Published: (2025)
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR‐mutated lung cancer treated with the first‐/second‐generation tyrosine kinase inhibitors
by: Michael Menzel, et al.
Published: (2024)
by: Michael Menzel, et al.
Published: (2024)
Clinicopathological and molecular spectrum of patients with germline SUFU mutations: A case series
by: Mashiro van Dal, et al.
Published: (2024)
by: Mashiro van Dal, et al.
Published: (2024)
Involvement of KEAP1/NRF2 pathway in non‐BRAF mutated squamous cell carcinoma of the thyroid
by: Elin Schoultz, et al.
Published: (2025)
by: Elin Schoultz, et al.
Published: (2025)
Unveiling the intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms
by: Lucas‐Alexander Schulte, et al.
Published: (2025)
by: Lucas‐Alexander Schulte, et al.
Published: (2025)
Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations
by: Jouni Härkönen, et al.
Published: (2026)
by: Jouni Härkönen, et al.
Published: (2026)
Clinicopathological characteristics and diagnostic accuracy of BRAF mutations in ameloblastoma: A Bayesian network analysis
by: Ao‐Bo Zhang, et al.
Published: (2024)
by: Ao‐Bo Zhang, et al.
Published: (2024)
Microfluidics‐based EGFR mutation detection and its implication in the resource‐limited clinical setting
by: Pradnya Joshi, et al.
Published: (2024)
by: Pradnya Joshi, et al.
Published: (2024)
TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma
by: Kaifeng Jin, et al.
Published: (2024)
by: Kaifeng Jin, et al.
Published: (2024)
Cutaneous Rosai–Dorfman disease with MAP2K1 mutation, initially mimicking an infection with parasitized histiocytes
by: Joseph Gillam, et al.
Published: (2024)
by: Joseph Gillam, et al.
Published: (2024)
The road to therapy for myeloid sarcoma: navigating the complexities of subclonal MAPK / ERK mutations and clonal evolution
by: DuJiang Yang, et al.
Published: (2025)
by: DuJiang Yang, et al.
Published: (2025)
Synchronous endometrial/cervical and ovarian/fallopian tube carcinoma: a genome‐wide mutation analysis
by: Lihong Li, et al.
Published: (2025)
by: Lihong Li, et al.
Published: (2025)
Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivoLMNA::NTRK1‐rearranged soft‐tissue sarcoma cell model
by: Yanjiang Chen, et al.
Published: (2024)
by: Yanjiang Chen, et al.
Published: (2024)
From morphology to methylome: epigenetic studies of Müllerian mesonephric‐like adenocarcinoma reveal similarities to cervical mesonephric adenocarcinoma†
by: Lawrence H Lin, et al.
Published: (2024)
by: Lawrence H Lin, et al.
Published: (2024)
A dominant negative Kcnd3 F227del mutation in mice causes spinocerebellar ataxia type 22 ( SCA22 ) by impairing ER and Golgi functioning
by: Hao‐Chih Hung, et al.
Published: (2024)
by: Hao‐Chih Hung, et al.
Published: (2024)
PIK3CA mutation status in apocrine carcinoma arising in apocrine gland hyperplasia/apocrine nevus: A study of four cases
by: Keisuke Goto, et al.
Published: (2024)
by: Keisuke Goto, et al.
Published: (2024)
Myeloid sarcoma shows a high frequency of mutations activating the MAPK/ERK pathway and association with clonal hematopoiesis
by: Dominik Nann, et al.
Published: (2025)
by: Dominik Nann, et al.
Published: (2025)
It was not possible to detect BRAF V600E mutation in circulating cell‐free DNA from patients with ameloblastoma: A diagnostic accuracy study
by: Allan Vinícius Martins‐de‐Barros, et al.
Published: (2024)
by: Allan Vinícius Martins‐de‐Barros, et al.
Published: (2024)
Somatic mutations in four novel genes contribute to homologous recombination deficiency in breast cancer: a real‐world clinical tumor sequencing study
by: Yongsheng Huang, et al.
Published: (2024)
by: Yongsheng Huang, et al.
Published: (2024)
Authors' reply: Re: Yang et al . The road to therapy for myeloid sarcoma: navigating the complexities of subclonal MAPK / ERK mutations and clonal evolution
by: Dominik Nann, et al.
Published: (2025)
by: Dominik Nann, et al.
Published: (2025)
Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom‐up approach
by: Marc Hilmi, et al.
Published: (2025)
by: Marc Hilmi, et al.
Published: (2025)
Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer
by: Sangkyou Lee, et al.
Published: (2025)
by: Sangkyou Lee, et al.
Published: (2025)
LINE ‐1 hypomethylation characterizes the inflammatory response in coeliac disease associated‐intestinal mucosa and small bowel adenocarcinomas
by: Laura Libera, et al.
Published: (2024)
by: Laura Libera, et al.
Published: (2024)
Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I–III micropapillary lung adenocarcinoma
by: Yang Qu, et al.
Published: (2025)
by: Yang Qu, et al.
Published: (2025)
Comparative transcriptomics of salivary basal cell adenoma and adenocarcinoma sustain linear neoplastic evolution and intertumor heterogeneity: classification and biological implications
by: Yoshitsugu Mitani, et al.
Published: (2025)
by: Yoshitsugu Mitani, et al.
Published: (2025)
RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma‐like mesenchymal tumors
by: Marialetizia Motta, et al.
Published: (2024)
by: Marialetizia Motta, et al.
Published: (2024)
Alternative driver pathways in peripheral nerve sheath tumors – including DICER1 and/or KRAS alterations
by: Hsin‐Yi Chang, et al.
Published: (2025)
by: Hsin‐Yi Chang, et al.
Published: (2025)
Prognostic significance of beta‐adrenergic receptor expression in oesophageal adenocarcinoma
by: Talita Oliveira, et al.
Published: (2026)
by: Talita Oliveira, et al.
Published: (2026)
Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas
by: Carmen Al Youssef, et al.
Published: (2025)
by: Carmen Al Youssef, et al.
Published: (2025)
Autopsy case of linear nevus sebaceous syndrome with KRAS (G12D) mutation
by: Akira Ohishi, et al.
Published: (2024)
by: Akira Ohishi, et al.
Published: (2024)
Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma
by: Deema Sabtan, et al.
Published: (2026)
by: Deema Sabtan, et al.
Published: (2026)
A quantitative tumor‐wide analysis of morphological heterogeneity of colorectal adenocarcinoma
by: Mihnea P Dragomir, et al.
Published: (2025)
by: Mihnea P Dragomir, et al.
Published: (2025)
PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT / mTOR signaling pathway
by: Hui Chen, et al.
Published: (2024)
by: Hui Chen, et al.
Published: (2024)
Expanding the clinicopathologic spectrum and genomic landscape of tumors with SMARCA2/4::CREM fusions
by: Joanna Cyrta, et al.
Published: (2024)
by: Joanna Cyrta, et al.
Published: (2024)
Similar Items
-
Molecular subtype concordance and metastatic patterns in muscle‐invasive bladder cancer
by: Csilla Olah, et al.
Published: (2026) -
Use of UV mutational signatures to distinguish between cutaneous and pulmonary primary squamous cell carcinoma
by: Jeffrey S. Ross, et al.
Published: (2024) -
Deep learning‐based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images
by: Jun Hyeong Park, et al.
Published: (2024) -
The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma
by: Ziqing Zeng, et al.
Published: (2024) -
TP53 mutations in urothelial carcinoma: not all one and the same†
by: Alexis R Barr, et al.
Published: (2024)